Foldax, Inc. today announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for the treatment of aortic valve disease. Clinicians at Beaumont Hospital, Royal Oak, in Michigan, implanted this innovative flexible polymer heart valve, which has the potential to address durability and thrombogenicity issues of currently available heart valves.
Dr. Marc Sakwa, Beaumont’s Chief of Cardiovascular Surgery, said, “The procedure was successfully performed on July 30th and the patient is doing well and has been discharged.”
Read more about it on Cardiac Vascular News: http://cardiacvascularnews.com/foldax-inc-successfully-completes-first-in-human-use-of-next-generation-tria-polymer-heart-valve-for-the-treatment-of-aortic-valve-disease/